CoChat
Sign Up
Cited by 205Regulation of Appetite and ObesityDiabetes Treatment and ManagementPharmacology and Obesity Treatment

The DOI matches its Crossref record; 48 of the 49 references it cites were found in a registry or an index.

Effect of pramlintide on satiety and food intake in obese subjects and subjects with type 2 diabetes

Open access
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., Horowitz, M.·2005·Diabetologia
DOI 10.1007/s00125-005-1732-4
Open this paper in CoChat — free accountOpen PDF

Abstract

Aims/hypothesis Long-term trials in insulin-treated subjects with type 2 diabetes have shown that adjunctive treatment with the amylin analogue pramlintide reduces HbA(1)c levels and elicits weight loss. While amylin reduces food intake in rodents, pramlintide's effect on satiety and food intake in humans has not yet been assessed. Methods In this randomised, double-blind, placebo-controlled crossover study, 11 insulin-treated men with type 2 diabetes (age 60+/-9 years, BMI 28.9+/-4.8 kg/m(2)) and 15 non-diabetic obese men (age 41+/-21 years, BMI 34.4+/-4.5 kg/m(2)) underwent two standardised meal tests. After fasting overnight, subjects received single subcutaneous injections of either pramlintide (120 microg) or placebo, followed by a preload meal. After 1 h, subjects ate an ad libitum buffet meal. Energy intake and meal duration were measured, as were hunger ratings (using visual analogue scales), and plasma cholecystokinin, glucagon-like peptide-1 and peptide YY concentrations over time. Results Compared with placebo, pramlintide reduced energy intake in both the type 2 diabetes (Delta-202+/-64 kcal, -23+/-8%, p<0.01) and obese (Delta-170+/-68 kcal, -16+/-6%, p<0.02) groups, without affecting meal duration. Hunger and hormonal analyte profiles provided evidence that pramlintide may exert a primary satiogenic effect, independently of other anorexigenic gut peptides. Conclusions/interpretation The results indicate that enhanced satiety and reduced food intake may explain the weight loss observed in long-term pramlintide trials.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1007/s00125-005-1732-4

Cites

48 of 48 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Show all 49 references

1 of the 49 references couldn’t be matched to a known paper.

Research works printed but not linked: 2

  1. Mack C, Hoyt J, Moore C, Jodka C, Sams-Dodd F (2003) Sustained reduction in food intake and body weight in high fat-fed rats during 28-day amylin infusion. Diabetes 52[Suppl 1]:A389 (Abstract 1690-P)
  2. World Health Organization (1995) Physical status: the use and interpretation of anthropometry. Report of a WHO Expert Committee. WHO Technical Report Series, 854. World Health Organization, Geneva

Cited by

Sorted by citations

Items 101–200 of 204

Related

See all

Metadata

Authors
Chapman, I., Parker, B., Doran, S., Feinle-Bisset, C., Wishart, J., Strobel, S., Wang, Y., Burns, C., Lush, C., Weyer, C., & Horowitz, M.
Affiliations
Royal Adelaide Hospital (AU)
Corresponding author
Weyer, C.
ORCID
Venue
Diabetologia
Publisher
Springer Science and Business Media LLC
Published
2005-04-21
Volume
48
Issue
5
Pages
838-848
ISSN
  • 0012-186X (ISSN-L)
  • 1432-0428
DOI
10.1007/s00125-005-1732-4
OpenAlex
W1965851116
Cited by
205
References
49
Citations by year
2026: 5 · 2025: 3 · 2024: 3 · 2023: 3 · 2022: 7 · 2021: 7 · 2020: 9 · 2019: 5 · 2018: 2 · 2017: 6 · 2016: 4 · 2015: 11 · 2014: 5 · 2013: 9 · 2012: 11
FWCI
8.21
Type
journal article
Language
en
Open access
Licence
www.springer.com/tdm (tdm)
Locations
  • Diabetologia (publishedVersion)
  • PubMed (publishedVersion)
  • Adelaide Research & Scholarship (AR&S) (University of Adelaide) (submittedVersion)
Topics
  • Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
Keywords
pramlintide, amylin analogues, satiety, dietary intake, obesity, type 2 diabetes, energy intake, hunger, cholecystokinin, glucagon-like peptide-1, peptide YY, weight loss, insulin-treated patients
MeSH terms
Adult, Amyloid, Energy Intake, Diabetes Mellitus, Type 2, Double-Blind Method, Energy Metabolism, Female, Humans, Hunger, Hypoglycemic Agents, Male, Middle Aged, Obesity, Placebos, Satiation, Body Mass Index, Diabetes Complications, Islet Amyloid Polypeptide

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review